跳至主要内容
临床试验/CTRI/2021/07/034867
CTRI/2021/07/034867已完成未知

Incidence of Major and Clinically Relevant Non-Major Bleeding (CRNMB) Among Covid 19 pneumonia Patients Receiving Therapeutic Heparin: A Retrospective Cohort Study

PGIMER Chandigarh0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1.All patients with age 18 years to 65 years.
  • 2.Confirmed COVID 19 from nasopharyngeal swap by Real time Polymerase chain reaction (RT PCR)
  • 3.Patients admitted to ICU and treated with therapeutic dosage of anti-coagulants. Therapeutic anticoagulation includes patients who receive LMWH at curative dose (100 IU/kg/12 h SC based on actual weight, without exceeding 10,000 IU/12 h or UFH 500 IU/kg/24 h if creatinine clearance < 30 mL/min.

排除标准

  • a)Patients who received prophylactic dose anticoagulants. This includes patients treated with standard or reinforced prophylactic dosage of heparin (low molecular weight heparin LMWH-enoxaparinâ??up to 6000 IU/12 h SC in obese patients or unfractionated heparin UFH 200 IU/kg/24 h if creatinine clearance < 30 mL/min).
  • b)Patients with a known bleeding disorder or evidence of active bleeding at the time of admission.
  • c)Any contraindication to the use of Heparin.

研究者

相似试验